--Two-Year Follow-Up Results Confirm Significant
Efficacy and No Serious Adverse Effects in Patients who Underwent
the StemSpine® Procedure for Treating Chronic Lower Back Pain
--
PHOENIX, Sept. 26,
2022 /PRNewswire/ -- Creative Medical Technology
Holdings, Inc. ("Creative Medical Technology" or the "Company")
(NASDAQ: CELZ), a leading biotechnology company focused on a
regenerative approach to immunotherapy, endocrinology, urology,
neurology, and orthopedics, today announced the peer reviewed
publication of positive, two-year follow-up data for the Company's
StemSpine® study, showing significant efficacy of the
StemSpine® procedure for treating chronic lower back
pain without any serious adverse effects reported.
The StemSpine® publication demonstrates the clinical
use of the patented procedure that utilizes a patient's own bone
marrow aspirate for the treatment of chronic lower back pain. There
were no safety related concerns at up to two years follow-up. The
StemSpine® procedure resulted in an efficacy rate of 87%
in the treated patients in terms of decreased pain and increased
mobility.
"The positive two-year data from our StemSpine® study
is very encouraging and may help alleviate the current opioid
crisis related to prescription medication abuse for chronic lower
back pain," said Timothy Warbington,
President and CEO of the Company. "To our knowledge, this is the
first demonstration of the clinical efficacy of injecting bone
marrow aspirate into areas surrounding the disc, which may repair,
remodel and improve the blood supply around the disc and lower back
area. We believe StemSpine® represents an attractive
non-surgical option for many of the millions of Americans who
suffer from chronic lower back pain and look forward to further
translation."
The StemSpine® patent also covers the use of off the
shelf adult donor stem cells (allogeneic) for this indication.
The publication may be found at
www.creativemedicaltechnology.com.
About Creative Medical Technology
Holdings
Creative Medical Technology Holdings, Inc. is a biotechnology
company specializing in regenerative medicine in the fields of
immunotherapy, endocrinology, urology, neurology, and orthopedics.
For further information about the Company, please visit
www.creativemedicaltechnology.com.
Forward Looking
Statements
This news release may contain forward-looking statements
including but not limited to comments regarding the timing and
content of upcoming clinical trials and laboratory results,
marketing efforts, funding, etc. Forward-looking statements address
future events and conditions and, therefore, involve inherent risks
and uncertainties. Actual results may differ materially from those
currently anticipated in such statements. See the periodic and
other reports filed by Creative Medical Technology Holdings, Inc.
with the Securities and Exchange Commission and available on the
Commission's website at www.sec.gov.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/creative-medical-technology-announces-peer-reviewed-publication-of-positive-results-for-stemspine-study-301632695.html
SOURCE Creative Medical Technology Holdings, Inc.